D'OXYVA® (deoxyhemoglobin vasodilator) is becoming a standard setter in numerous fields and the first choice of doctors around the world for the treatment of the most difficult complications caused by chronic diseases such as diabetes, cardiovascular, and various forms of cancer such as multiple myeloma.


D'OXYVA is intended for significant enhancements in the regulation of the autonomic nervous system (ANS) including tissue microcirculation with cellular oxygenation (Bohr & Haldane effect), which is being recognized in a rapidly growing number of published randomized clinical trials leading to a variety of significant clinical outcomes. In short, D'OXYVA has demonstrated unmatched increases in blood circulation, cellular oxygenation, tissue perfusion in the microvessels, and neural signal activation in the autonomic nervous system according to randomized human clinical trials.

Microcirculation and autonomic nervous system dysfunction is increasingly regarded by the mainstream scientific medical community as the underlying cause of the most widespread health complications for both the young and elderly. Among other things, restrictions in these processes impede normal organ functions, the flow of antibodies, white blood cells and platelets, and rob the skin and body of oxygen and essential nutrients.

Safety & Cost

D'OXYVA is a relatively affordable low risk, non-invasive, non-toxic, both adjunct and standalone solution for the forward-looking health facility and patient wanting to significantly reduce cost of treatment and readmission rates, while improving patient compliance.

Recommended Regimen

The recommended average starting dose of D'OXYVA is 16g CO2 twice daily for 5 days per week for the first 2 weeks and once daily for 5 days per week for another 2 weeks. The average maintenance dose of D'OXYVA can be once a day for 3 days per week. The starting and maintenance dose of D'OXYVA should be individualized according to patient characteristics such as goals of therapy and response.

Recommended Diagnostics

Blood flow (perfusion index), oxygen (SpO2 and TcPO2), blood pressure, blood glucose, heart rate variability, sympathetic/parasympathetic nerve activity, blood pH, and other vitals should be analyzed within 2 to 4 weeks after starting D'OXYVA and dosage adjusted according to results.

Stopping D'OXYVA after only 4 weeks is not recommended and it may not provide the expected long-term benefits even if major benefits and clinical outcomes were realized!

D'OXYVA is becoming exceptionally advantageous for the patient, health care practitioner, and the entire healthcare system, and is starting to provide substantial cost savings and improvements in quality of life for a wide variety of health complications for people of all ages and backgrounds.

Summary Page of Clinical Evidence

Expert Feedback

Scientific Publications of Clinical Evidence